Board of Directors

Ian Smith MBE, BMedSc(Hons), MB, ChB - Chairman
Ian founded Synexus, the world’s leading clinical Site Management Organisation (SMO), in 1998 and acted as Global Medical Director until 2014. Ian has been involved in over 1500 clinical trials in a variety of areas. He has led feasibility on approximately 200 protocols per year for over 18 years and was recently awarded the Institute of Clinical Research “Award for Outstanding Achievement”. He was also awarded an MBE for Services to Health Research in the New Year’s Honours List 2012. In addition to the abundance of clinical expertise Ian brings to the team, he has a wealth of business experience, including the listing of Synexus Ltd onto AIM and eventual sale to Lyceum Capital.

Liberty Foreman PhD - CEO

Liberty graduated from the University of Sussex in 2011 in Molecular Genetics. Whilst studying she developed a keen interest in bioinformatics. This led her to complete her PhD in 2015 at UCL in clinical data analytics. During her research she developed the algorithm behind the BeamLine system. Whilst studying and working between clinicians and computational statisticians, she realised that so much research lacked efficient multi-disciplinary collaboration. In 2014 she was awarded a fellowship from the Software Sustainability Institute for her collaborative work between statisticians and clinicians. Liberty co-founded BeamLine Diagnostics in March 2015. Liberty manages the development of the BeamLine algorithm, as well as working with the rest of the BeamLine team on strategic planning.

Katherine Willetts PhD - COO

After graduating from the University of Warwick in 2011 with a BSc. in Biochemistry Katie became interested in translational medicine and biophysics. She went on to complete her PhD at UCL in 2015 in the technical development of infrared spectroscopy for biomedical applications. She has published several papers relating to the handling and analysis of biological samples in infrared spectroscopy research. Several aspects of her research have proven key in the development of the BeamLine algorithm. Katie co-founded BeamLine Diagnostics in March 2015 and continues to work on technical development and data analysis.

Savvas Neophytou PhD - Deepbridge Capital

Dr Savvas Neophytou is partner at Deepbridge Capital and Head of Life Sciences. Prior to joining Deepbridge in January 2016 Savvas enjoyed a 15 year career in the City, working as an investment banker and ECM at JP Morgan, Bear Stearns, Shore Capital, Cantor Fitzgerald and Panmure Gordon. As a highly acclaimed analyst he won multiple awards, most recently in 2015, when Savvas was ranked 2nd overall in the prestigious Reuters Starmine survey, a position he also held in 2014. In the same year, he was also runner up in the CityAM Analyst of the Year awards. Savvas holds a PhD in psychopharmacology from Nottingham University and a BSc (Hons) degree in pharmacology from Manchester University.

Tim Mustill - Angel Investor

Working in the medical industry for the past 20 years Tim has vast expertise in commercial strategy, marketing and medical affairs. Tim was appointed to the board in April 2017 and will represent angel investors from London Business Angels, London Co-investment Fund, Angel Academe, Minerva, Wild Blue Cohort and Pemco Holding.